{
  "0": "Aquatic Ecotoxicology",
  "1": "Serotonin Receptor Modulation in SSRI Treatment",
  "2": "Analytical Methods for SSRI Detection and Quantification",
  "3": "SSRIs for OCD",
  "4": "Risk of Prenatal Exposure",
  "5": "SSRIs for Pediatric Depression",
  "6": "SSRIs and the Cytochrome P450 System",
  "7": "Impact of SSRIs on Neurogenesis",
  "8": "The Chronic Unpredictable Mild Stress Model of Depression",
  "9": "SSRIs Effect on Neural Processing of Emotional Cues",
  "10": "Risk of Prenatal Exposure (Rodents)",
  "11": "SSRIs for PTSD",
  "12": "SSRIs in Forced Swimming Test",
  "13": "SSRI Utilization Patterns",
  "14": "Fluvoxamine for Depression",
  "15": "Inflammatory Biomarkers",
  "16": "Sexual Dysfunction",
  "17": "SSRIs Effect on Fear",
  "18": "Post-Stroke SSRI Use",
  "19": "Escitalopram for Depression",
  "20": "Serotonin Transporter Gene and Antidepressant Response",
  "21": "Treatment Strategies and Outcomes in Depression",
  "22": "SSRIs for Pain",
  "23": "SSRIs for Depression in Patients with Cardiovascular Disease",
  "24": "SSRIs in Dementias",
  "25": "Serotonin Syndrome",
  "26": "SSRIs for Weight Management",
  "27": "Paroxetine Binding to Serotonin Transporter",
  "28": "Bleeding Risk",
  "29": "Antidepressant-like Effects of Herbal Extracts in Animal Models",
  "30": "Oncopreventive and Oncolytic Properties of SSRIs",
  "31": "Suicice Risk",
  "32": "Fracture Risk",
  "33": "SSRIs for Generalized Anxiety Disorder",
  "34": "SSRIs for Panic Disorder",
  "35": "Pharmacological Reviews",
  "36": "SSRIs for Bipolar Depression",
  "37": "Hepatotoxic Risk",
  "38": "Fluvoxamine for Covid 19",
  "39": "Pharmacoeconomics of SSRIs for Depression",
  "40": "SSRIs Effect on Sleep",
  "41": "Venlafaxine vs SSRIs for Depression",
  "42": "SSRI Effects on Lactation",
  "43": "SSRIs for Depression in Diabetes Patients",
  "44": "SSRIs for Menopausal Vasomotor Symptoms (Hot flashes)",
  "45": "Pharmacovigilance of SSRIs",
  "46": "Premature Ejaculation",
  "47": "SSRIs for Depression with Cognitive Impairment",
  "48": "QTC Prolongation",
  "49": "Extrapyramidal Reactions Risk",
  "50": "SSRIs for Irritable Bowel Syndrome",
  "51": "SSRIs for Alcohol Dependence",
  "52": "SSRIs for Premenstrual Dysphoric Disorder (PMDD)",
  "53": "Neuroimaging of Serotonin Transporters",
  "54": "SSRIs for (Psycho)dermatological Diseases",
  "55": "Synthetic Chemistry of Paroxetine",
  "56": "SSRIs for Autism Spectrum Disorders",
  "57": "SSRIs for Eating Disorders",
  "58": "SSRIs for Depression in Parkinsons Patients",
  "59": "SSRIs for Depression in in Epileptic Patients",
  "60": "SSRIs Effects on Ion Channels",
  "61": "SSRIs and Augmentation for Treatment Resistant Depression",
  "62": "Environmental Degradation of Antidepressants",
  "63": "Methylenedioxymethamphetamine (MDMA) Induced Neurotoxicity",
  "64": "Laboratory Techniques for drug analysis",
  "65": "SSRIs for Social Anxiety Disorder",
  "66": "Forensic Toxicology of Fatal Overdoses",
  "67": "SSRIs (Fluvoxamine) for Schizophrenia",
  "68": "SSRIs Effect on Pulmonary Hypertension",
  "69": "SSRIs for Body Dysmorphic Disorder (BDD)",
  "70": "Antidepressant Drug Design",
  "71": "Serotonergic Modulation of Cocaine Effects",
  "72": "Pharmacogenetics in SSRI Treatment",
  "73": "Non-SERT Transporters in Antidepressant Action",
  "74": "SSRIs for Depression, Comparative Effectiveness",
  "75": "SSRIs for Geriatric Depression",
  "76": "SERT Binding Mechanisms",
  "77": "Astrocyte Receptors as a Target for SSRIs",
  "78": "SSRIs for Borderline Personality Disorder",
  "79": "Agomelatin for Depression",
  "80": "Depression Treatment Guidelines",
  "81": "Sertraline for Depression",
  "82": "Withdrawal Symptoms",
  "83": "Hyponatremia Risk",
  "84": "SSRIs Effect on Dopamine Receptors",
  "85": "SSRIs Effects on Antimicrobials and Gut Microbiome",
  "86": "SSRIs for Depression after Traumatic Brain Injury",
  "87": "Antifungal Activity of Sertraline",
  "88": "Neurometabolite Changes with Antidepressants",
  "89": "Galanin System in Antidepressant Action",
  "90": "SSRIs for Fibromyalgia",
  "91": "SSRI Crystal Structure and Complexation",
  "92": "SSRIs Effect on Brain-derived Neurotrophic Factor (BDNF) Levels in Depressive Patients",
  "93": "SSRIs in Model Organisms ( C. Elegans and Drosophilia)",
  "94": "SSRIs for Depression in Cancer Patients",
  "95": "SSRIs for Postpartum Depression",
  "96": "SSRIs Long-term Efficacy and Recurrent Depression",
  "97": "Canine Behavioral Disorders",
  "99": "SRRIs and Ocular Safety"
}
